A Safe, Blood-Brain Barrier Permeable Triphenylmethane Dye Inhibits Amyloid-β Neurotoxicity by Generating Nontoxic Aggregates
Authors:
- Wei QiWQWei Qi
- Erik J. FernandezEFErik J. Fernandez
- Inchan KwonIKInchan Kwon
- 26 September 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 2 (11) , 645-657
Abstract
Growing evidence suggests that on-pathway amyloid-β (Aβ) oligomers are primary neurotoxic species and have a direct correlation with the onset of Alzheimer’s disease (AD). One promising therapeutic strategy to block AD progression is to reduce the levels of these neurotoxic Aβ species using small molecules. While several compounds have been shown to modulate Aβ aggregation, compounds with such activity combined with safety and high blood-brain barrier (BBB) permeability have yet to be reported. Brilliant Blue G (BBG) is a close structural analogue of a U.S. Food and Drug Administration (FDA)-approved food dye and has recently garnered prominent attention as a potential drug to treat spinal cord injury due to its neuroprotective effects along with BBB permeability and high degree of safety. In this work, we demonstrate that BBG is an effective Aβ aggregation modulator, which reduces Aβ-associated cytotoxicity in a dose-dependent manner by promoting the formation of off-pathway, nontoxic aggregates. Comparative studies of BBG and three structural analogues, Brilliant Blue R (BBR), Brilliant Blue FCF (BBF), and Fast Green FCF (FGF), revealed that BBG is most effective, BBR is moderately effective, and BBF and FGF are least effective in modulating Aβ aggregation and cytotoxicity. Therefore, the two additional methyl groups of BBG and other structural differences between the congeners are important in the interaction of BBG with Aβ leading to formation of nontoxic Aβ aggregates. Our findings support the hypothesis that generating nontoxic aggregates using small molecule modulators is an effective strategy for reducing Aβ cytotoxicity. Furthermore, key structural features of BBG identified through structure–function studies can open new avenues into therapeutic design for combating AD.Keywords
This publication has 87 references indexed in Scilit:
- Beta‐barrel models of soluble amyloid beta oligomers and annular protofibrilsProteins: Structure, Function, and Bioinformatics, 2010
- Effects of Congo Red on Aβ1−40 Fibril Formation Process and MorphologyACS Chemical Neuroscience, 2010
- Two Disaccharides and Trimethylamine N-Oxide Affect Aβ Aggregation Differently, but All Attenuate Oligomer-Induced Membrane PermeabilityBiochemistry, 2009
- Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 miceProceedings of the National Academy of Sciences, 2009
- Structural Differences between Aβ(1-40) Intermediate Oligomers and Fibrils Elucidated by Proteolytic Fragmentation and Hydrogen/Deuterium ExchangeBiophysical Journal, 2009
- EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomersNature Structural & Molecular Biology, 2008
- Simultaneous monitoring of peptide aggregate distributions, structure, and kinetics using amide hydrogen exchange: Application to Aβ(1‐40) fibrillogenesisBiotechnology and Bioengineering, 2008
- Congo red and protein aggregation in neurodegenerative diseasesBrain Research Reviews, 2007
- Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse modelNature Medicine, 2006
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976